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OBJECTIVE: To estimate the long-term beneﬁts of
chemopreventive tamoxifen and mammography screen-
ing in women who are healthy but at high risk of devel-
oping breast cancer. Long-term beneﬁts were deﬁned in
terms of life expectancy (LE) gains achieved through 
addition of chemopreventive tamoxifen (5-year therapy)
to routine mammography screening.
METHOD: A Markov process with time-and-
state-dependent transition probabilities was developed.
Two hypothetical cohorts of high-risk women were 
initiated at age forty and were followed over their lifetime.
The ﬁrst cohort consumed tamoxifen and underwent
routine mammography screening as per recommendations
of the American Cancer Society (ACS). The second cohort
(control cohort) did not consume tamoxifen and under-
went mammography screening at rates observed in general
population settings (these rates are much lower than the
ones recommended by the ACS). Tamoxifen intervention
was modeled based on the 5-year Breast Cancer Preven-
tion Trial results. Data from published analyses, which
investigated effects of mammography screening on breast
cancer mortality, was used to model mammography
screening intervention. Mortality data were obtained from
life tables and other published sources.
RESULTS: Tamoxifen coupled with routine mammogra-
phy screening prolonged the average survival of cohort
members who started consuming the drug at age of forty
by 86.14 days as compared to the control group. One-way
sensitivity analysis was performed to evaluate the poten-
tial impact of each assumption on average cohort survival.
Sensitivity analysis involved varying intervention-related
effectiveness parameters, rates of intervention-related
adverse events, compliance with intervention, and mor-
tality rates associated with different health states in the
model. For all variations, tamoxifen plus routine mam-
mography screening group had higher average survival
than the control group.
CONCLUSION: The model was found to be robust to
sensitivity analysis and hence tamoxifen plus routine
mammography screening can be expected to increase 
survival among women who are at higher risk of 
breast cancer.
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OBJECTIVES: To identify and compare the costs 
and outcomes associated with early intensiﬁcation with
bone marrow transplantation versus conventional dose
chemotherapy for previously untreated patients with
aggressive non-Hodgkin’s lymphoma at high risk for
relapse.
METHODS: Costs and patient responses (outcomes)
were evaluated for the ﬁrst 84 patients in this ongoing
prospective randomized clinical trial. Data were compiled
from November 1995 until May 2001. Patient outcomes
were retrieved from the institutional Protocol Data 
Management System and costs were retrieved from 
institutional ﬁnancial and administrative databases.
Direct costs included hospital, clinic, pharmacy, and
physician costs. Pearson chi square was used to analyze
the association between costs and treatment group.
RESULTS: Forty-four patients received conventional 
dose chemotherapy and 40 patients received BMT. The 
average cost of therapy per patient for conventional dose
chemotherapy was $61,515 (range $5,360 to $186,684)
and the average cost per patient for BMT was $133,365
(range $11,868 to $431,248). Outcomes were categorized
as complete response (n = 36), partial response (n = 35),
and other (incomplete to date n = 13). Costs were 
categorized as low (<$45,000), medium ($45,000–
$80,999), medium high ($81,000–$125,999), and high
(>$126,000). In the conventional dose chemotherapy
group 61.1% of patients had a complete response and
38.9% of patients in the BMT group had a complete
response. Costs for conventional dose chemotherapy
patients were in the low to medium cost groups, and costs
for BMT patients were in the medium-high to high cost
groups (chi square = 29.422, d.f. = 3, p < 0.001).
CONCLUSIONS: Overall, higher costs were observed in
the BMT group, and more complete responses were
observed in the conventional dose chemotherapy group.
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OBJECTIVES: To evaluate infectious disease outcomes
and cost of care for lymphoma and myeloma patients
admitted for infectious complications. To evaluate a 
Palm handheld as a tool for prospective data collection
utilizing Pendragon Forms software.
METHODS: Patients admitted to the Lymphoma/
Myeloma service receiving anti-infective therapy for
infectious diseases were followed. Targeted outcomes
were collected prospectively during hospitalization and
included length of hospitalization (days), adverse events
attributed to the anti-infective, febrile days (≥38.3°C),
